Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment

Last updated: February 20, 2024
Sponsor: Chinese University of Hong Kong
Overall Status: Active - Recruiting

Phase

N/A

Condition

Prostate Cancer, Early, Recurrent

Prostate Cancer

Prostate Disorders

Treatment

N/A

Clinical Study ID

NCT05761093
CRE-2022.301
  • Ages > 18
  • Male

Study Summary

The objective of this study is to examine the preference weightings in term of risk/ benefit attributes of treatment in physician and prostate cancer patients from different stages of disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • aged 18 years or older,
  • diagnosis of metastatic prostate cancer within 5 years,
  • able to read and write,
  • accepting and signing the informed consent

Exclusion

Exclusion Criteria:

  • if patients are unable to complete the survey by themselves due to physical orpsychological reasons,
  • deemed ineligible by treating physicians if patients are unable to complete the surveyby themselves due to physical or psychological reasons,
  • deemed ineligible by treating physicians

Study Design

Total Participants: 306
Study Start date:
September 07, 2022
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Prince of Wales Hospital

    Sha Tin,
    Hong Kong

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.